# Charlie Petty

> Charlie Petty is a Series A investor at Adjuvant Capital backing Biotechnology. See 15 investments, check sizes, portfolio and contact details. Updated Aug…

- Type: Angel Investor
- Fund: [Adjuvant Capital](https://shizune.co/investors/profile/adjuvant-capital)
- Location: New York, United States
- Total investments: 15
- Last investment: Oct 2025
- Lead investor: 40%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/charlespetty
- X (Twitter): https://twitter.com/@chuck_petty

Charlie Petty is a Series A investor at Adjuvant Capital in New York focused on Biotechnology and Health Care. Charlie helped found Adjuvant Capital from the Global Health Investment Fund (GHIF), where he was responsible for sourcing and executing investments in medical device companies, including the fund’s investments in IanTech (acquired by Zeiss) and Alydia Health.Prior to GHIF, Charlie was with Artemis Capital Partners, where he made private equityinvestments in industrial technology companies with a focus on the scientific instrumentation and advanced materials sectors. Previously, he lived and worked in Haiti at the country’s largest microfinance bank, Sevis Finansye Fonkoze, where he led financial and operational analysis efforts. Charlie remains actively involved in Haiti and serves on the boards of Sevis Finansye Fonkoze and Fonkoze USA.He is a graduate of the Virginia Polytechnic Institute.

## Contacts

5 contacts available for Charlie Petty: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/charles-petty?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 33% |
| Health Care | 4 | 27% |
| Industrial | 3 | 20% |
| Manufacturing | 3 | 20% |
| Medical Device | 3 | 20% |

23 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 27% |
| Series B | 4 | 27% |
| Series C | 3 | 20% |
| Seed | 1 | 7% |
| Private Equity | 1 | 7% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| VitriVax | VitriVax is a biotech startup that develops a vaccine formulation platform. VitriVax's proprietary technology, created at the University of Colorado with the support of over $5M from NIH, NSF and the State of Colorado, and most recently, $2.2M from the Bill and Melinda Gates Foundation, makes human and animal vaccines more effective, moreaffordable, and more accessible globally.VitriVax is headquartered in Boulder, Colorado. | $17.3M | Series B | Oct 22, 2025 |  |
| Curevo | Curevo is a clinical-stage biotech firm focused on producing next-generation vaccines that brings effectiveness, safety, tolerability, and advanced production capabilities to the market. Curevo's lead product, a sub-unit Zoster (Shingles) Vaccine, has completed Phase I (90 subject trial). Results are showing a promising safety profile and thedesired immune responses. They are targeting a unique position in the $7B Varicella Zoster Virus vaccine market. | $110M | Series B | Mar 17, 2025 |  |
| Codagenix | Codagenix is a developer of live-attenuated viral vaccines intended to provide target antigens placed in an attenuated backbone virus.The company's vaccines use Synthetic Attenuated Virus Engineering (SAVE), which are based on synthetic biology and are rationally re-designed of the entire genome to yield a vaccine strain, enabling researchersto invent viral vaccine to treat influenza, dengue, polio, and other diseases. Codagenix has been developing a COVID-19 vaccine as well. | $25M | Series B | Feb 15, 2023 |  |
| Curevo | Curevo is a clinical-stage biotech firm focused on producing next-generation vaccines that brings effectiveness, safety, tolerability, and advanced production capabilities to the market. Curevo's lead product, a sub-unit Zoster (Shingles) Vaccine, has completed Phase I (90 subject trial). Results are showing a promising safety profile and thedesired immune responses. They are targeting a unique position in the $7B Varicella Zoster Virus vaccine market. | $26M | Series A | Nov 16, 2022 |  |
| Endpoint Health | Endpoint Health is a precision immunology company that is breaking the efficacy barrier of traditional pharma's “one-size-fits-all” drug development strategy by developing precision therapies with outsized efficacy potential in autoimmune and inflammatory conditions. They’re accomplishing this by leveraging OMNAI, their proprietary AI-poweredpatient discovery platform, to identify and match high-potential therapies to the patients most likely to respond. | $52M | Series A | Jun 02, 2022 |  |
| Curevo | Curevo is a clinical-stage biotech firm focused on producing next-generation vaccines that brings effectiveness, safety, tolerability, and advanced production capabilities to the market. Curevo's lead product, a sub-unit Zoster (Shingles) Vaccine, has completed Phase I (90 subject trial). Results are showing a promising safety profile and thedesired immune responses. They are targeting a unique position in the $7B Varicella Zoster Virus vaccine market. | $60M | Series A | Jan 07, 2022 |  |
| VitriVax | VitriVax is a biotech startup that develops a vaccine formulation platform. VitriVax's proprietary technology, created at the University of Colorado with the support of over $5M from NIH, NSF and the State of Colorado, and most recently, $2.2M from the Bill and Melinda Gates Foundation, makes human and animal vaccines more effective, moreaffordable, and more accessible globally.VitriVax is headquartered in Boulder, Colorado. |  | Series A | Jul 07, 2021 |  |
| Alydia Health | Alydia Health is a medical device company working toward a solution to postpartum hemorrhage (PPH), the number one cause of maternal death. Our single-minded focus is to improve radically the treatment path for postpartum hemorrhage from the traumatic, life-altering condition that it is today. We are devoted to improving the lives of women aroundthe world.Alydia Health was previously known as InPress Technologies, Inc. | $13.9M | Series C | Jul 30, 2020 |  |
| ChromaCode | ChromaCode is a molecular diagnostics company focusing on bioinformatics. It leverages patented mathematical methods and algorithmic enhancements to enrich signal processing from life science instrumentation. The company uses this to extract new information on biochemistry reactions and substantially increase the performance capabilities of today’sgold-standard biochemical assays at a very low cost.ChromaCode was founded in 2012, ChromaCode is headquartered in Carlsbad, California. | $10M | Series C | May 19, 2020 |  |
| Alydia Health | Alydia Health is a medical device company working toward a solution to postpartum hemorrhage (PPH), the number one cause of maternal death. Our single-minded focus is to improve radically the treatment path for postpartum hemorrhage from the traumatic, life-altering condition that it is today. We are devoted to improving the lives of women aroundthe world.Alydia Health was previously known as InPress Technologies, Inc. | $10.3M | Series B | Aug 28, 2018 |  |

10 of 15 investments shown.

## Co-investors
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 4 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 4 deals together
- [GC Biopharma](https://shizune.co/investors/profile/green-cross-holdings-corp) — VC Fund, 3 deals together
- [Mayfield Fund](https://shizune.co/investors/profile/mayfield-fund) — VC Fund, 2 deals together
- [Alix Ventures](https://shizune.co/investors/profile/alix-ventures) — VC Fund, 1 deal together
- [AME Cloud Ventures](https://shizune.co/investors/profile/ame-cloud-ventures) — VC Fund, 1 deal together

## About Adjuvant Capital

VC Fund · New York, United States

Adjuvant Capital is a life sciences investment firm focused on global health. The company makes $10-$25 million investments in ambitious companies targeting opportunities in high burden and neglected disease. Adjuvant Capital was founded in 2012 by Charlie Petty, Glenn Rockman, and Kabeer Aziz and is based in New York.

5 contacts available at Adjuvant Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Glenn Rockman | Founder and Managing Partner | — |
| Michael Chang | Principal | — |
| Charlie Petty | Principal | — |
| Jenny Yip | Managing Partner | — |
| Kabeer Aziz | Principal | https://shizune.co/investors/profile/kabeer-aziz |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Charlie Petty invest in?

Charlie Petty invests primarily in Biotechnology, Health Care and Industrial startups, most often at Series A and Series B stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Charlie Petty?

Public channels for Charlie Petty include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Charlie Petty last invest?

The most recent investment recorded for Charlie Petty closed in Oct 2025. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co